158144-79-7

Basic information

• Product Name: 1-N-BOC-4-PHENYLPIPERIDINE-4-CARBONITRILE
• Synonyms: 1-N-BOC-4-PHENYLPIPERIDINE-4-CARBONITRILE;TERT-BUTYL 4-CYANO-4-PHENYLPIPERIDINE-1-CARBOXYLATE;1-Boc-4-cyano-4-phenylpiperidine;Tert-butyl 4-cyano-4-phenyl-1-piperidinecarboxylate
• CAS NO: 158144-79-7
• Molecular Formula: C₁₇H₂₂N₂O₂
• Molecular Weight: 286.38
• Mol File: 158144-79-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-N-BOC-4-PHENYLPIPERIDINE-4-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-4-PHENYLPIPERIDINE-4-CARBONITRILE(158144-79-7)
• EPA Substance Registry System: 1-N-BOC-4-PHENYLPIPERIDINE-4-CARBONITRILE(158144-79-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 158144-79-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry Research:
1-N-BOC-4-PHENYLPIPERIDINE-4-CARBONITRILE is used as a research compound for the synthesis of other complex organic compounds. Its BOC-protected structure makes it a valuable intermediate in the preparation of various pharmaceuticals and chemical products.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 1-N-BOC-4-PHENYLPIPERIDINE-4-CARBONITRILE is used as a key intermediate in the synthesis of drugs. Its role is crucial in the development of new medications, where its reactivity and structural properties contribute to the formation of the desired active pharmaceutical ingredients.
Used in Chemical Production:
1-N-BOC-4-PHENYLPIPERIDINE-4-CARBONITRILE is employed as a custom synthesis material in the chemical production industry. Its use is instrumental in creating a wide range of chemical products, from specialty chemicals to advanced materials, where its unique properties are harnessed to achieve specific outcomes.

InChI:InChI=1S/C17H22N2O2/c1-16(2,3)21-15(20)19-11-9-17(13-18,10-12-19)14-7-5-4-6-8-14/h4-8H,9-12H2,1-3H3

Upstream product

• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 140-29-4 phenylacetonitrile 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 34619-03-9 tert-butyldicarbonate 
• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 
• 71999-74-1 tert-butyl N-(2-chloroethyl)carbamate 

Downstream Products

• 158144-82-2 tert. butyl 4-aminomethyl-4-phenyl-piperidine-1-carboxylate 
• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 158144-80-0 1-Boc-4-phenyl-4-piperidinecarbaldehyde 
• 172734-33-7 4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 
• 1292306-44-5 ethyl 5-(4-phenylpiperidin-4-yl)pentanoate hydrochloride 
• 1292306-45-6 C₂₁H₂₉NO₄ 
• 1292306-46-7 C₂₁H₃₁NO₄ 
• 716360-31-5 tert-butyl 4-(3-oxopropyl)-4-phenylpiperidine-1-carboxylate 
• 1292306-47-8 C₂₃H₃₃NO₄ 
• 1292360-02-1 C₂₃H₃₅NO₄ 
• 1071485-35-2 N-((1-(4-chloro-3-sulfamoylbenzoyl)-4-phenylpiperidin-4-yl)methyl)-3-fluoro-4-(2-(4-methylpyridin-2-ylamino)thiazol-5-ylthio)picolinamide hydrochloride 
• 1071485-37-4 N-((1-(1-aminocyclopropanecarbonyl)-4-phenylpiperidin-4-yl)methyl)-3-fluoro-4-(2-(4-methylpyridin-2-ylamino)thiazol-5-ylthio)picolinamide hydrochloride 
• 1071483-71-0 N-((1-(2-(dimethylamino)acetyl)-4-phenylpiperidin-4-yl)methyl)-3-fluoro-4-(2-(4-methylpyridin-2-ylamino)thiazol-5-ylthio)picolinamide hydrochloride 
• 1071484-39-3 3-fluoro-N-((1-(2-hydroxy-2-methylpropyl)-4-phenylpiperidin-4-yl)methyl)-4-(2-(4-methylpyridin-2-ylamino)thiazol-5-ylthio)picolinamide hydrochloride 

Relevant articles and documents

PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Described herein are compounds that act as CYP46A1 inhibitors, compositions comprising these compounds, and methods of their use into treating neurodegenerative diseases and the like, or a pharmaceutically active salt thereof. The present invention relates to compounds represented by the formula wherein each symbol is as defined in the specification, or a pharmaceutically active salt thereof.

Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity

Targeting of Akt has been validated as a well rationalized approach to cancer treatment, and represents a promising therapeutic strategy for aggressive hematologic malignancies. We describe herein an exploration of novel Akt inhibitors for cancer therapy through structural optimization of previously described 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives. Our studies yielded a novel series of pyrrolopyrimidine based phenylpiperidine carboxamides capable of potent inhibition of Akt1. Notably, 10h exhibited robust antiproliferative effects in both mantle cell lymphoma cell lines and primary patient tumor cells. Low micromolar doses of 10h induced cell apoptosis and cell cycle arrest in G2/M phase, and significantly downregulated the phosphorylation of Akt downstream effectors GSK3β and S6 in Jeko-1 cells.

A nitrogen-containing heterocyclic phenyl piperidine compound and its preparation method and application

The invention discloses a nitrogen-containing heterocyclic phenyl piperidine compound or pharmaceutical salt thereof. The general structural formula a of the compound is as shown in specification, wherein R represents hydrogen, mono-substituted or poly-substituted halogen, methyl, methoxyl, tertiary butyl or trifluoromethyl; and R2 is hydrogen, chlorine, bromine, methyl or ethyl. The compound disclosed by the invention is novel in structure; and by introducing the active amino in the form of a piperidine ring, the configuration of the side-chain amino is reinforced and the rigidity of the compound is enhanced. Through the design transformation, the Akt1 kinase inhibitory activity and the PC-3 cell line growth inhibitory activity of the compound are significantly enhanced.

HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF

The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF

The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile

We recently described (J. Med. Chem. 2008, 51, 6538-6546) a novel class of CCR5 antagonists with strong anti-HIV potency. Herein, we detail SAR converting leads 1 and 2 to druglike molecules. The pivotal structural motif enabling this transition was the secondary sulfonamide substituent. Further finetuning of the substituent pattern in the sulfonamide paved the way to enhancing potency and bioavailability and minimizing hERG inhibition, resulting in discovery of clinical compound 122 (GSK163929).

Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold

One approach to ameliorate the cognitive decline in Alzheimer's disease (AD) has been to restore neuronal signaling from the basal forebrain cholinergic system via the activation of the M1 muscarinic receptor. A number of nonselective M1 muscarinic agonists have previously shown positive effects on cognitive behaviors in AD patients, but were limited due to cholinergic adverse events thought to be mediated by the activation of the M2 to M5 subtypes. One strategy to confer selectivity for M1 is the identification of positive allosteric modulators, which would target an allosteric site on the M1 receptor rather than the highly conserved orthosteric acetylcholine binding site. Quinoline carboxylic acids have been previously identified as highly selective M1 positive allosteric modulators with good pharmacokinetic and in vivo properties. Herein is described the optimization of a novel quinolizidinone carboxylic acid scaffold with 4-cyanopiperidines being a key discovery in terms of enhanced activity. In particular, modulator 4i gave high plasma free fractions, enhanced central nervous system (CNS) exposure, was efficacious in a rodent in vivo model of cognition, and afforded good physicochemical properties suitable for further preclinical evaluation.

[2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring

Several series of CCR5 antagonists have been discovered by derivatization at the N-terminal of the piperidine ring of the core template 2. Some derivatives exhibited potent inhibition against HIV-1infection. The pharmacokinetic properties of the lead comp

Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1

We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the 125I-[MIP-1β] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC50 = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC50 = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.